Latest Headlines

Latest Headlines

Medgenics seeks $29.4M to finance Biopump line

Drug delivery giant Medgenics ($MEDG) is looking to collect $29.4 million in an effort to develop and commercialize its Biopump delivery platform designed to treat anemia, hepatitis and hemophilia.

Medgenics treats first dialysis patients with biological EPO pumps

Medgenics has begun a Phase IIa trial of its Epodure Biopump, delivering sustained-release EPO (erythropoietin) in dialysis patients with end-stage renal disease. This trial is the first evaluation of the company's technology as an anemia treatment in this patient group.

Discovery reveals possible way to engineer blood vessels to deliver drugs

Children's Hospital Boston researchers believe they have may have found a way to genetically engineer blood vessels to secrete recombinant, protein-based drugs directly into the bloodstream--on...